NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $21.47 +0.15 (+0.70 %) (As of 05/22/2019 07:43 AM ET)Previous Close$21.32Today's Range$21.15 - $21.4752-Week Range$15.04 - $25.43Volume70,062 shsAverage Volume181,369 shsMarket Capitalization$1.01 billionP/E Ratio102.24Dividend YieldN/ABeta1.36 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; lidocaine jelly, a local anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection for newborn babies; and morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as recombinant human and porcine insulins. Further, the company has a pipeline of 20 product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. Receive AMPH News and Ratings via Email Sign-up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMPH Previous Symbol CUSIPN/A CIK1297184 Webhttp://www.amphastar.com/ Phone909-980-9484Debt Debt-to-Equity Ratio0.11 Current Ratio2.06 Quick Ratio1.35Price-To-Earnings Trailing P/E Ratio102.24 Forward P/E Ratio102.24 P/E GrowthN/A Sales & Book Value Annual Sales$294.67 million Price / Sales3.43 Cash Flow$0.5719 per share Price / Cash Flow37.54 Book Value$8.08 per share Price / Book2.66Profitability EPS (Most Recent Fiscal Year)$0.21 Net Income$-5,740,000.00 Net Margins0.74% Return on Equity5.14% Return on Assets3.63%Miscellaneous Employees2,078 Outstanding Shares47,065,000Market Cap$1.01 billion Next Earnings Date8/14/2019 (Estimated) OptionableOptionable Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions What is Amphastar Pharmaceuticals' stock symbol? Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH." How will Amphastar Pharmaceuticals' stock buyback program work? Amphastar Pharmaceuticals announced that its board has initiated a stock repurchase program on Thursday, August 10th 2017, which allows the company to buyback $20,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 2.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its shares are undervalued. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) released its quarterly earnings data on Thursday, May, 9th. The company reported $0.10 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.03 by $0.07. The firm earned $79.79 million during the quarter, compared to analysts' expectations of $76.21 million. Amphastar Pharmaceuticals had a net margin of 0.74% and a return on equity of 5.14%. The business's revenue for the quarter was up 36.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.05 earnings per share. View Amphastar Pharmaceuticals' Earnings History. When is Amphastar Pharmaceuticals' next earnings date? Amphastar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Amphastar Pharmaceuticals. What price target have analysts set for AMPH? 4 analysts have issued twelve-month target prices for Amphastar Pharmaceuticals' shares. Their forecasts range from $22.20 to $26.00. On average, they expect Amphastar Pharmaceuticals' stock price to reach $23.7333 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price. View Analyst Price Targets for Amphastar Pharmaceuticals. What is the consensus analysts' recommendation for Amphastar Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amphastar Pharmaceuticals. Has Amphastar Pharmaceuticals been receiving favorable news coverage? Media headlines about AMPH stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amphastar Pharmaceuticals earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Amphastar Pharmaceuticals' key competitors? Some companies that are related to Amphastar Pharmaceuticals include United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), American Brivision (Holding) (ABVC), Evotec (EVTCY), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), Amicus Therapeutics (FOLD) and Arena Pharmaceuticals (ARNA). What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Mattel (MAT), Ultra Clean (UCTT), General Electric (GE), American National BankShares (AMNB), Enterprise Bancorp (EBTC), Gilead Sciences (GILD), Twitter (TWTR), US Foods (USFD) and Amicus Therapeutics (FOLD). Who are Amphastar Pharmaceuticals' key executives? Amphastar Pharmaceuticals' management team includes the folowing people: Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 69)Dr. Yongfeng Zhang, CEO, Chief Science Officer & Director (Age 72)Mr. Jason B. Shandell, Pres, Gen. Counsel & Director (Age 45)Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 51)Mr. Jacob Liawatidewi M.B.A., Sr. VP of Corp. Admin. Center, Sales and Marketing & Corp. Sec. (Age 45) Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.41%), Dimensional Fund Advisors LP (4.09%), Federated Investors Inc. PA (3.13%), Geode Capital Management LLC (0.94%), Renaissance Technologies LLC (0.94%) and Morgan Stanley (0.80%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, Stephen B Shohet, William J Peters and Yakob Liawatidewi. View Institutional Ownership Trends for Amphastar Pharmaceuticals. Which major investors are selling Amphastar Pharmaceuticals stock? AMPH stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc., Parametric Portfolio Associates LLC, SEI Investments Co, Argent Capital Management LLC, Rothschild & Co. Asset Management US Inc., Wells Fargo & Company MN and BlueMountain Capital Management LLC. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi. View Insider Buying and Selling for Amphastar Pharmaceuticals. Which major investors are buying Amphastar Pharmaceuticals stock? AMPH stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, Federated Investors Inc. PA, Goldman Sachs Group Inc., Alambic Investment Management L.P., Sawgrass Asset Management LLC, California Public Employees Retirement System and Schonfeld Strategic Advisors LLC. View Insider Buying and Selling for Amphastar Pharmaceuticals. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Amphastar Pharmaceuticals' stock price today? One share of AMPH stock can currently be purchased for approximately $21.47. How big of a company is Amphastar Pharmaceuticals? Amphastar Pharmaceuticals has a market capitalization of $1.01 billion and generates $294.67 million in revenue each year. The company earns $-5,740,000.00 in net income (profit) each year or $0.21 on an earnings per share basis. Amphastar Pharmaceuticals employs 2,078 workers across the globe. What is Amphastar Pharmaceuticals' official website? The official website for Amphastar Pharmaceuticals is http://www.amphastar.com/. How can I contact Amphastar Pharmaceuticals? Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected] MarketBeat Community Rating for Amphastar Pharmaceuticals (NASDAQ AMPH)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 282 (Vote Outperform)Underperform Votes: 221 (Vote Underperform)Total Votes: 503MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: What is the Quick Ratio? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.